The global Advanced Therapy Medicinal Products Market is expanding rapidly as pharmaceutical and biotechnology companies increasingly invest in cell therapy, gene therapy, tissue-engineered products, regenerative medicine, and personalized therapeutics. These advanced therapies are being developed for cancer, rare genetic disorders, cardiovascular diseases, neurological conditions, and other serious diseases. Continuous advances in viral-vector manufacturing, stem-cell processing, genome editing, and precision medicine are supporting commercialization and broader adoption of advanced therapeutic products.

According to Fortune Business Insights, the global advanced therapy medicinal products market was valued at USD 44.20 billion in 2025 and is projected to grow from USD 51.75 billion in 2026 to USD 182.60 billion by 2034, exhibiting a CAGR of 17.07% during the forecast period.

Why is the Advanced Therapy Medicinal Products Market Growing?

The rising demand for personalized medicine and regenerative healthcare is one of the strongest factors driving the market. CAR-T therapies, stem-cell therapies, and gene-editing technologies are increasingly being developed to target disease mechanisms at the molecular level and provide more personalized therapeutic approaches.

Advanced therapy medicinal products are increasingly being developed for:

• Oncology
• Rare genetic diseases
• Neurological disorders
• Cardiovascular diseases
• Autoimmune diseases
• Musculoskeletal conditions
• Regenerative medicine
• Tissue repair
• Immunotherapy
• Genetic disorders

Pharmaceutical companies and biotechnology firms are also investing heavily in advanced manufacturing capabilities, precision medicine technologies, and specialized research infrastructure.

Key Market Trends Shaping Industry Growth

Increasing Adoption of Cell and Gene Therapies

Cell therapy is the leading therapy type, accounting for approximately 46% of the market. Growing adoption of CAR-T immunotherapies, stem-cell therapies, and other autologous and allogeneic cell-based treatments is driving segment growth.

Gene therapy represents approximately 34% of the market and is supported by increasing development of therapies for inherited genetic disorders, retinal diseases, hemophilia, neuromuscular diseases, and other conditions.